ATLANTA, Sept. 30, 2016 /PRNewswire/ -- On Saturday, October 1, 2016, Arbor Pharmaceuticals, LLC (Arbor) will be honored by the Association of Black Cardiologists (ABC) with their "Spirit of the Heart" Health Equity Award. The award will be presented at the ABC's seventh annual "Spirit of the Heart" Awards Dinner at Cipriani 42nd Street.
Each year, the gala recognizes individuals and organizations that have made exceptional contributions to cardiology and the advancement of health equity by eliminating cardiovascular disease disparities. Proceeds from the celebration support ABC's "Spirit of the Heart" community outreach program, which provides people with information and resources for heart disease prevention.
"Arbor is driven by a mission to identify, develop and market pharmaceutical products that improve the quality of life for our patients. In our efforts toward this mission, we proudly support the work of ABC in promoting equity in cardiovascular health," said Ed Schutter, president and CEO of Arbor. "Our commitment to developing pharmaceutical products that reduce health care disparities is enhanced by our partnership with ABC and all healthcare providers who exemplify the 'Spirit of the Heart.'"
Arbor is the only pharmaceutical company that offers a treatment option proven to be particularly effective in self-identified African Americans, BiDil (isosorbide dinitrate/hydralazine).
In addition to the company's marketed products, its commitment to the health of African Americans is also reflected in its partnerships and community involvement. Arbor recently launched a heart failure awareness campaign aimed at educating this population about chronic heart failure, as well as spotlighting the disproportionate impact of the disease on African Americans.
The community events bring together nurse practitioners, community leaders, patients, caregivers, and physicians for an open dialogue about reducing the impact of heart failure at the individual and community levels. The events drive awareness by sharing resources, healthy lifestyle tips and strategies for managing and preventing heart failure in communities where heart failure rates are on the rise.
Arbor has previously partnered with physician advocates on cardiovascular awareness and education initiatives.
About Arbor Pharmaceuticals
Arbor Pharmaceuticals, LLC headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital, neurology and pediatric markets. The company has over 700 employees. Arbor currently markets over twenty NDA or ANDA approved products with over 35 more in development.
For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to email@example.com.
Please click on below link for full Prescribing Information.
INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.
IMPORTANT SAFETY INFORMATION
BiDil is contraindicated in patients who are allergic to organic nitrates or who take a phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Concomitant use can cause hypotension.
WARNINGS AND PRECAUTIONS
Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome. Symptoms and signs usually regress when hydralazine hydrochloride is discontinued. Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil. Hypotension is most likely to occur in patients who have been volume or salt depleted; correct prior to initiation of BiDil. Hydralazine hydrochloride can cause tachycardia and hypotension potentially leading to myocardial ischemia and angina, particularly in patients with hypertrophic cardiomyopathy.
Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect. Pyridoxine should be added to BiDil therapy if such symptoms develop.
Most common adverse reactions (> 5% more on BiDil than on placebo) were headache and dizziness.
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.